

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The products are primarily used at emergency departments in hospitals for risk stratification of acute medical patients to improve clinical decisions on discharge and hospitalization.

ViroGates' suPARnostic® product range measures the protein, suPAR (soluble urokinase Plasminogen Activator Receptor). The protein is naturally occurring in human blood and reflects the immune system's activation level. A patient's suPAR level predicts negative outcomes such as short-term mortality across acute and chronic diseases. The suPARnostic® tests are easily integrated into existing hospital workflows and instruments, and the results are available in 10-20 minutes.

The company was founded in 2000 based on the discovery that suPAR was predictive of the outcome in HIV infections and subsequently in many other disease areas. Headquartered in Birkerød, Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) have been listed on Nasdaq First North Growth Market Denmark since 2018.

● ViroGates



Share Data		26/07/2021
Previous Close		155.00
Change (%)		0.32
Volume		1,351
Number of Shares		3,170,083
Market Cap		491.36

KEY FIGURES - DKK('000)

	2020	2019
Income statement		
Net revenue	5,354	3,582
Operating profit/loss	-19,729	-19,723
Profit/loss for the year	-18,736	-18,797
Balance sheet		
Balance sheet total	38,246	45,157
Equity	31,314	42,215
Invested capital	895	2,942
Cash flows		
Cash flows from operating activities	-15,602	-18,073
Cash flows from investment related activities	-114	-603
Cash flows from financing activities	7,835	-
Total cash flows	-7,881	-18,676
Cash and cash equivalents	33,526	41,407
Ratios		
Rate of return	-1,028.1	-736.8
Number of employees, end of period	14	12
Market share price, end of period (DKK)	81.5	34.3


MAJOR SHAREHOLDERS

At the end of 2020, ViroGates had 1,161 registered shareholders. Three shareholders had notified shareholdings of 5% or more:

Shareholders (31/12/2020)	Number Of Shares	Percent Of Capital
N.P. LOUIS-HANSEN APS	817,075	26.14%
KIM GINNERUP APS	325,965	10.43%
4AM APS	325,965	10.43%



Sales by product (2020)



- 38% Turbilatex
- 20% Quick Triage
- 40% ELISA
- 2% Other*

* Other includes analysis services, freight and handling